slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
214,771-214,800 of 319,975
06
Uses a 'Before-After-Bridge' style logic to frame the solution.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
Uses a process/timeline diagram to show life cycle management.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
The slide highlights business development traction through licensing agreements.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
09
Matinas BioPharma | Investor Presentation Deck | 28 slidesMatinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
10
The chart displays survival percentages with corresponding n/N values below each bar group.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
11
The slide uses a timeline-like visualization for each patient to show the rapid decline of fungal load over a short period (12-14 days).Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
12
The slide uses a timeline-based process diagram to illustrate the clinical trial protocol.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
13
IFIs stands for Invasive Fungal Infections.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
14
Case study table showing patient demographics, medical history, and treatment outcomes.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
15
Matinas BioPharma | Investor Presentation Deck | 28 slidesMatinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
16
The slide serves as a transition to the technology/pipeline section of the deck.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
17
Matinas BioPharma | Investor Presentation Deck | 28 slidesMatinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
18
Includes a scientific diagram of the LNC structure and a list of key performance attributes.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
19
The slide uses a process diagram to show the self-assembly of lipoplexes into PS-NPs.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
20
Technical slide detailing biological mechanism of drug delivery platform.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
21
Uses a process-flow diagram to represent maturity levels (Proven, Under Evaluation, Future).Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
22
The slide compares Matinas' PS-NP technology stability (17 weeks) against Moderna (30 days) and Pfizer/BioNTech (10 weeks) at refrigerated temperatures.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
23
The slide shows quantitative radiance data (p/s/cm²/sr) comparing control groups to PS-NP LUC mRNA groups at various time points.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
24
The slide highlights a partnership with 'Resilience' to scale manufacturing for Matinas Biopharma's therapeutic platforms.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
25
The slide uses a grid-based timeline format to track specific technical achievements and partnership milestones.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
26
The slide uses a three-column icon-based layout to summarize key IP milestones.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
27
Matinas BioPharma | Investor Presentation Deck | 28 slidesMatinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Team1 hit
28
The slide uses a split-layout: left side for financial summary, right side for milestones and thesis components.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
01
Matson | Results Presentation Deck | 19 slidesMatson | Results Presentation Deck | 19 slides · Matson
Conference presentation Investor relations 1 hit
02
Matson | Results Presentation Deck | 19 slidesMatson | Results Presentation Deck | 19 slides · Matson
Conference presentation Investor relations 1 hit
03
Matson | Results Presentation Deck | 19 slidesMatson | Results Presentation Deck | 19 slides · Matson
Conference presentation Investor relations Beat · Attention1 hit
04
The chart compares 2022 and 2023 quarterly container volumes, with a specific callout for the Q2 YoY decline.Matson | Results Presentation Deck | 19 slides · Matson
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
05
Includes a dual-axis line chart and a summary table of economic projections.Matson | Results Presentation Deck | 19 slides · Matson
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
06
The chart compares 2022 vs 2023 quarterly container volumes.Matson | Results Presentation Deck | 19 slides · Matson
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
07
Matson | Results Presentation Deck | 19 slidesMatson | Results Presentation Deck | 19 slides · Matson
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit